A Phase II study of SHR-A1921, a TROP2-targeted antibody-drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma.

Saved in:
Bibliographic Details
Title: A Phase II study of SHR-A1921, a TROP2-targeted antibody-drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma.
Authors: Chen GL; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Guo Y; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Yang Y; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Sang Y; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Sun S; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Liu X; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Zhou X; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China., Sheng CY; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China., He X; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China., Wang J; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China., Shi R; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China., Wang Y; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China., Ji Q; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China., Ji D; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. jid09@fudan.edu.cn.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. jid09@fudan.edu.cn.
Source: NPJ precision oncology [NPJ Precis Oncol] 2026 May 13. Date of Electronic Publication: 2026 May 13.
Publication Type: Journal Article
Journal Info: Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol
Database: MEDLINE Ultimate
Description
ISSN:2397-768X
DOI:10.1038/s41698-026-01463-5